ERBB2 and lung carcinoma: TKIs targeting ERBB2 have limited activity in patients with ERBB2-positive tumors [37,38], although some case series have reported that lung cancer patients with ERBB2 20ins can benefit from TKIs, such as afatinib [39] and poziotinib [40].